Rhopressa Solution/ Drops
Product Images NDC 70727-497

This appears to be a report or analysis of clinical trial data comparing two medications, Rhopressa and Timolol, for their impact on intraocular pressure in subjects with a baseline IOP of less than 26 mmHg. The data includes measurements taken at various times of day on different days, and shows the change from baseline IOP for both medications. Additionally, the results of the two medications are compared and expressed as the difference between them, along with a 95% confidence interval.*

This appears to be a table showing the results of Study 301 with Rhopressa and Timolol on subjects with Baseline IOP. The table shows the visit numbers, baseline IOP readings, IOP readings at different times on days 15, 43, and 90, as well as the change from the baseline. It also shows the differences in IOP levels between Rhopressa and Timolol, with confidence intervals.*

This is a table that represents the change in intraocular pressure (IOP) in subjects with a baseline IOP below 25 mmHg. The subjects were given Rhopressa and Timolol. The table shows the IOP readings at different visits (baseline, day 15, day 43, and day 90) and times (8am, 10am, 4pm). The difference between the two medications is presented at the bottom.*

This appears to be a table showing data from Study 302 regarding subjects with a certain baseline intraocular pressure (IOP) range. The table includes measurements taken at different timepoints for two different treatments: Rhopressa and Timolol, with a column showing the difference between the two treatments. The table also shows changes from baseline for each treatment at different timepoints. However, the values seem to be partially illegible and difficult to interpret.*

This appears to be a table of results from a clinical study comparing the eye pressure-lowering effects of two treatments, Rhopressa and Timolol, over a period of 90 days on 186 subjects with a baseline eye pressure below 26 mmHg. The table shows eye pressure measurements at different times of day on each visit, as well as the change from baseline at day 15, day 43, and day 90. The last row shows the difference between the two treatments with a 95% confidence interval.*

This text presents a table with different measurements of IOP (in mmHg) for subjects with baseline IOP values between 25 and 30. The table shows measurements at different timepoints (including baseline, day 15, day 43, and day 90) as well as changes from baseline. Additionally, the table provides values for subjects receiving Rhopressa and Timolol, including the difference between the two treatments.*

Rhopressa is an ophthalmic solution used to treat high intraocular pressure and open-angle glaucoma. It is available in a 2.5mL bottle, and the usual dosage is one drop in the affected eye(s) once a day in the evening. Each mL of the solution contains nearsightedness mesylate 0.285 mg. The solution should be stored at 20-25°C (68-77°F) and refrigerated at 2-8°C (36-46°F) once opened. The product can be used for up to six weeks after opening if kept refrigerated. The solution is sterile and for topical application in the eye. The solution comes with a 2D code and human-readable data, and it is available only through prescription from Pramaceticas nc, Irvine CA 92614. However, the text also contains a warning that the is of B 6pt font (1.4 mm minimum character height) with all uppercase, and some of the text might not be readable.*

This is a description of a medication called Rhopressa® by Aerie Pharmaceuticals Inc. It is an ophthalmic solution used for topical application in the eye. The solution comes in a 2.5mL bottle, and one dose is affected (369-46°F) when unopened. Once opened, the product should be refrigerated at 2-8°C and may last up to two weeks. The solution includes a preservative, and the inactive ingredients include boric acid, sodium hydroxide, and mannitol. The product's NDC code is 70727-497-99, and its Rx-only. The text includes additional details for adjusting pH and water for injection.*